 BASEL, Switzerland and NEW YORK, Feb. 17, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV and Pfizer Inc. NYSE: PFE today announced publication in the New England Journal of Medicine of the Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg in women with uterine fibroids. As previously reported, both studies achieved the primary endpoint of response rates in menstrual blood loss in addition to six of the seven key secondary endpoints, while maintaining bone mineral density comparable to placebo as part of a well-tolerated safety profile over 24 weeks. 